Targeted Proteomics Combined with Affinity Mass Spectrometry Analysis Reveals Antagonist E7 Acts As an Intracellular Covalent Ligand of Orphan Receptor GPR52

Mengna Ma,Shimeng Guo,Xi Lin,Shanshan Li,Yiran Wu,Yanping Zeng,Youhong Hu,Suwen Zhao,Fei Xu,Xin Xie,Wenqing Shui
DOI: https://doi.org/10.1021/acschembio.0c00867
IF: 4.634
2020-12-01
ACS Chemical Biology
Abstract:The GPR52, a class A orphan G protein-coupled receptor (GPCR), is regarded as a promising therapeutic target for the treatment of Huntington's disease and multiple psychiatric disorders. Although the recently solved structure of GPR52 has revealed a binding mechanism likely shared by all reported agonists, the small molecule antagonist E7 cannot fit into this agonist-binding pocket, and its interaction mode with the receptor remains unknown. Here, we employed targeted proteomics and affinity mass spectrometry approaches to uncover a unique binding mode of E7 which acts as a covalent and allosteric ligand of GPR52. Among three Cys residues identified in this study to form covalent conjugates with E7, the intracellular C156<sup>4.40</sup> makes the most significant contribution to the antagonism activity of E7. Discovery of this novel intracellular site for covalent attachment of an antagonist would facilitate the design of GPR52-selective negative allosteric modulators which could serve as potential therapeutics for treating Huntington's disease.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acschembio.0c00867?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acschembio.0c00867</a>.(Figure S1) Purification of the GPR52 protein; (Figure S2) structure and cell activity of a newly synthesized GPR52 antagonist (Comp-43); (Figure S3) E7 is covalently conjugated to GPR52 expressed in live cells; (Figure S4) molecular docking of reported agonists into the agonist-binding side pocket in the GPR52 structure; (Figure S5) surface expression levels of WT and mutant GPR52 as determined by FACS staining of HEK293/HA-GPR52 cells; (Table S1) targeted MS peak intensities of E7-modified peptides and unmodified counterparts from purified GPR52 protein; (Table S2) targeted MS peak intensities of E7-modified peptides and unmodified counterparts from GPR52 in live cells; (Table S3) targeted MS peak intensities of E7-modified peptides and unmodified counterparts from purified GPR52 protein pretreated with or without 7m (<a class="ext-link" href="/doi/suppl/10.1021/acschembio.0c00867/suppl_file/cb0c00867_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.
biochemistry & molecular biology
What problem does this paper attempt to address?